Product
GEN3009
Aliases
DuoHexaBody®-CD37
1 clinical trial
8 indications
Indication
Diffuse Large B-cell LymphomaIndication
Follicular LymphomaIndication
Marginal Zone LymphomaIndication
Small Lymphocytic LymphomaIndication
mantle cell lymphomaIndication
Chronic Lymphocytic LeukemiaIndication
High-grade B-cell lymphomaClinical trial
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion CohortsStatus: Terminated, Estimated PCD: 2022-11-21